These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 18635918

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.
    Matsumoto T, Ono Y, Kurono M, Kuromiya A, Nakamura K, Bril V.
    J Pharmacol Sci; 2009 Feb; 109(2):203-10. PubMed ID: 19212096
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy.
    Asano S, Himeno T, Hayami T, Motegi M, Inoue R, Nakai-Shimoda H, Miura-Yura E, Morishita Y, Kondo M, Tsunekawa S, Kato Y, Kato K, Naruse K, Nakamura J, Kamiya H.
    J Diabetes Res; 2019 Feb; 2019():2756020. PubMed ID: 31828158
    [Abstract] [Full Text] [Related]

  • 5. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
    Sekiguchi K, Kohara N, Baba M, Komori T, Naito Y, Imai T, Satoh J, Yamaguchi Y, Hamatani T, Ranirestat Group.
    J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462
    [Abstract] [Full Text] [Related]

  • 6. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K, Kato N, Matsubara A, Nakano K, Kurono M.
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [Abstract] [Full Text] [Related]

  • 7. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H.
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
    Giannoukakis N.
    Expert Opin Investig Drugs; 2008 Apr; 17(4):575-81. PubMed ID: 18363521
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ranirestat for the management of diabetic sensorimotor polyneuropathy.
    Bril V, Hirose T, Tomioka S, Buchanan R, Ranirestat Study Group.
    Diabetes Care; 2009 Jul; 32(7):1256-60. PubMed ID: 19366965
    [Abstract] [Full Text] [Related]

  • 13. Characterization of a novel aldose reductase inhibitor, TAT, and its effects on streptozotocin-induced diabetic neuropathy in rats.
    Inukai S, Agata M, Sato M, Naitou A, Matsukawa H, Goto M.
    Jpn J Pharmacol; 1993 Mar; 61(3):221-7. PubMed ID: 8483299
    [Abstract] [Full Text] [Related]

  • 14. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
    Ashizawa N, Yoshida M, Sugiyama Y, Akaike N, Ohbayashi S, Aotsuka T, Abe N, Fukushima K, Matsuura A.
    Jpn J Pharmacol; 1997 Feb; 73(2):133-44. PubMed ID: 9074947
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of ranirestat for the treatment of diabetic neuropathy.
    Giannoukakis N.
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1051-9. PubMed ID: 24785785
    [Abstract] [Full Text] [Related]

  • 16. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
    Hara T, Nakamura J, Koh N, Sakakibara F, Hamada Y, Sasaki H, Naruse K, Nakashima E, Takeuchi N, Inukai S.
    J Lab Clin Med; 1995 Dec; 126(6):541-7. PubMed ID: 7490513
    [Abstract] [Full Text] [Related]

  • 17. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat.
    Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T, Ohkubo Y, Notsu Y, Yamaguchi I.
    Metabolism; 1991 Jan; 40(1):77-87. PubMed ID: 1898618
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
    Polydefkis M, Arezzo J, Nash M, Bril V, Shaibani A, Gordon RJ, Bradshaw KL, Junor RW, Ranirestat Study Group.
    J Peripher Nerv Syst; 2015 Dec; 20(4):363-71. PubMed ID: 26313450
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.